Mitochondria-targeted resveratrol derivatives act as cytotoxic pro-oxidants
Resveratrol derivatives bearing an O-linked mitochondria-targeting 4-triphenylphosphoniumbutyl group at either position 3 or position 4' are prooxidant and cytotoxic for cultured cells, selectively killing fast-growing cells when supplied in the low μM range. Resveratrol is essentially without...
Saved in:
Published in | Current pharmaceutical design Vol. 20; no. 2; p. 172 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United Arab Emirates
01.01.2014
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | Resveratrol derivatives bearing an O-linked mitochondria-targeting 4-triphenylphosphoniumbutyl group at either position 3 or position 4' are prooxidant and cytotoxic for cultured cells, selectively killing fast-growing cells when supplied in the low μM range. Resveratrol is essentially without effect under these experimental conditions, while the cytotoxicity of the mitochondriotropic derivatives increases if they are methylated on the remaining hydroxyls. Experiments with Bax(-/-)/Bak(-/-) cells and a pan-caspase inhibitor show that cell death is mostly of the necrotic type. Cytotoxicity is due to ROS produced upon accumulation of the compounds into mitochondria, and specifically to H2O2, since externally added membrane-permeant catalase largely prevents cell death while superoxide dismutase potentiates toxicity. The mitochondriotropic compounds cause ROS-independent depolarization of in situ mitochondria. Effectiveness is increased if resveratrol hydroxyls are acetylated or methylated; this excludes the involvement of autooxidation of the polyphenolic nucleus and a protonophoric cycle as the causes of ROS generation and of depolarization, respectively. Resveratrol-triphenylphosphonium conjugates may thus represent a new class of chemotherapeutic agents, redox-active "mitocans", whose mechanisms of action and in vivo activity are worthy of further investigation. |
---|---|
AbstractList | Resveratrol derivatives bearing an O-linked mitochondria-targeting 4-triphenylphosphoniumbutyl group at either position 3 or position 4' are prooxidant and cytotoxic for cultured cells, selectively killing fast-growing cells when supplied in the low μM range. Resveratrol is essentially without effect under these experimental conditions, while the cytotoxicity of the mitochondriotropic derivatives increases if they are methylated on the remaining hydroxyls. Experiments with Bax(-/-)/Bak(-/-) cells and a pan-caspase inhibitor show that cell death is mostly of the necrotic type. Cytotoxicity is due to ROS produced upon accumulation of the compounds into mitochondria, and specifically to H2O2, since externally added membrane-permeant catalase largely prevents cell death while superoxide dismutase potentiates toxicity. The mitochondriotropic compounds cause ROS-independent depolarization of in situ mitochondria. Effectiveness is increased if resveratrol hydroxyls are acetylated or methylated; this excludes the involvement of autooxidation of the polyphenolic nucleus and a protonophoric cycle as the causes of ROS generation and of depolarization, respectively. Resveratrol-triphenylphosphonium conjugates may thus represent a new class of chemotherapeutic agents, redox-active "mitocans", whose mechanisms of action and in vivo activity are worthy of further investigation. |
Author | Paradisi, Cristina Azzolini, Michele Zoratti, Mario Mattarei, Andrea Szabo', Ildiko' Sassi, Nicola Biasutto, Lucia Bernardi, Paolo |
Author_xml | – sequence: 1 givenname: Nicola surname: Sassi fullname: Sassi, Nicola – sequence: 2 givenname: Andrea surname: Mattarei fullname: Mattarei, Andrea – sequence: 3 givenname: Michele surname: Azzolini fullname: Azzolini, Michele – sequence: 4 givenname: Paolo surname: Bernardi fullname: Bernardi, Paolo – sequence: 5 givenname: Ildiko' surname: Szabo' fullname: Szabo', Ildiko' – sequence: 6 givenname: Cristina surname: Paradisi fullname: Paradisi, Cristina – sequence: 7 givenname: Mario surname: Zoratti fullname: Zoratti, Mario – sequence: 8 givenname: Lucia surname: Biasutto fullname: Biasutto, Lucia email: lucia.biasutto@unipd.it organization: CNR Institute of Neuroscience, c/o Dept. of Biomedical Sciences, Viale Giuseppe Colombo 3, 35121 Padova, Italy. lucia.biasutto@unipd.it |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/23701548$$D View this record in MEDLINE/PubMed |
BookMark | eNo1j8lKBDEURYMo9qB_IJIfKM1LUhmW0jhhixtdNy9DaUl3pUhiYf-9DerdnLM6cBfkeEhDJOQC2BUHLa9BGFDADYAAexhjQh6RORgtGsmNmpFFKZ-MAbcgT8mMC82glWZOnp77mvxHGkLusamY32ONgeZYppix5rSlIeZ-wtpPsVD0lWKhfl9TTd-9p2NOzUECDrWckZMOtyWe_3FJ3u5uX1cPzfrl_nF1s26cFLw2WgRl0XRGKeTcOCG5Q2jRgmbYGhW5tBhCEMCUMa12zrNO-9ajQKNt4Ety-dsdv9wuhs2Y-x3m_eb_Ff8Bon5Qww |
CitedBy_id | crossref_primary_10_1038_cddis_2015_263 crossref_primary_10_3390_cancers15030666 crossref_primary_10_1007_s12010_022_04252_5 crossref_primary_10_1089_ars_2017_7404 crossref_primary_10_1016_j_isci_2023_108659 crossref_primary_10_1021_acs_chemrev_7b00042 crossref_primary_10_15252_embr_201643354 crossref_primary_10_3390_molecules25225443 crossref_primary_10_1080_14756366_2018_1442831 crossref_primary_10_1016_j_bmcl_2020_127234 crossref_primary_10_1021_acsomega_1c05515 crossref_primary_10_1002_JLB_5VMR0818_330RR crossref_primary_10_3390_antiox8080244 crossref_primary_10_1016_j_bbagen_2016_01_017 crossref_primary_10_1016_j_bcp_2023_115953 crossref_primary_10_3390_cancers11070916 crossref_primary_10_1039_C9MD00572B crossref_primary_10_3390_molecules28031057 crossref_primary_10_1021_acs_jmedchem_7b00679 crossref_primary_10_1111_jfbc_13008 crossref_primary_10_3390_molecules27031001 crossref_primary_10_3390_toxics5040038 crossref_primary_10_1111_nyas_13401 crossref_primary_10_1016_j_phrs_2017_07_016 crossref_primary_10_1016_j_bbabio_2014_06_010 crossref_primary_10_3390_pharmaceutics13081205 crossref_primary_10_1016_j_ejmech_2019_07_060 crossref_primary_10_1016_j_biocel_2018_02_007 crossref_primary_10_2147_IJN_S303832 crossref_primary_10_1021_acs_jmedchem_8b01052 crossref_primary_10_3390_antibiotics12020401 crossref_primary_10_1016_j_phrs_2021_105959 crossref_primary_10_1016_j_canlet_2015_07_004 crossref_primary_10_1111_bph_13954 crossref_primary_10_1371_journal_pone_0144290 crossref_primary_10_1158_1940_6207_CAPR_20_0425 crossref_primary_10_3390_ijms23105572 crossref_primary_10_1038_srep08088 |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.2174/13816128113199990034 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1873-4286 |
ExternalDocumentID | 23701548 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- .5. 0R~ 29F 36B 3V. 4.4 53G 5GY 69Q 7X7 88E 8AO 8FI 8FJ 8R4 8R5 AAEGP ABEEF ABJNI ABUWG ABVDF ACGFO ACGFS ACITR ACIWK ACPRK ADBBV AENEX AFKRA AFRAH AFUQM AGJNZ AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS ANTIV BENPR BPHCQ BVXVI C1A CCPQU CGR CS3 CUY CVF DU5 EBS ECM EIF EJD F5P FYUFA GH2 HMCUK HZ~ IPNFZ KCGFV KFI M1P NPM O9- P2P PQQKQ PROAC PSQYO Q2X RIG UKHRP |
ID | FETCH-LOGICAL-b432t-73d69a8f866a228b342ba15a9170a586e249addd31068857bbc0f7c5ca3a879d2 |
IngestDate | Sat Sep 28 08:34:41 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-b432t-73d69a8f866a228b342ba15a9170a586e249addd31068857bbc0f7c5ca3a879d2 |
PMID | 23701548 |
ParticipantIDs | pubmed_primary_23701548 |
PublicationCentury | 2000 |
PublicationDate | 2014-01-01 |
PublicationDateYYYYMMDD | 2014-01-01 |
PublicationDate_xml | – month: 01 year: 2014 text: 2014-01-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | United Arab Emirates |
PublicationPlace_xml | – name: United Arab Emirates |
PublicationTitle | Current pharmaceutical design |
PublicationTitleAlternate | Curr Pharm Des |
PublicationYear | 2014 |
SSID | ssj0012914 |
Score | 2.3477643 |
Snippet | Resveratrol derivatives bearing an O-linked mitochondria-targeting 4-triphenylphosphoniumbutyl group at either position 3 or position 4' are prooxidant and... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 172 |
SubjectTerms | Animals bcl-2 Homologous Antagonist-Killer Protein - genetics bcl-2-Associated X Protein - genetics Cell Death - drug effects Cells, Cultured Dose-Response Relationship, Drug Gene Knockout Techniques Hydrogen Peroxide - metabolism Mice Mitochondria - drug effects Mitochondria - metabolism Necrosis - pathology Oxidants - administration & dosage Oxidants - chemistry Oxidants - pharmacology Oxidation-Reduction Reactive Oxygen Species - metabolism Resveratrol Stilbenes - administration & dosage Stilbenes - chemistry Stilbenes - pharmacology |
Title | Mitochondria-targeted resveratrol derivatives act as cytotoxic pro-oxidants |
URI | https://www.ncbi.nlm.nih.gov/pubmed/23701548 |
Volume | 20 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Li9swEBbZ9tJL6ftddCh7WrWxLEvycSktS0uXhWZhb4seYxpok9CYpcmhv70zluNoQ0ofF2Os4Ah_n8ea0cw3jL1qDHivIiW1AwhlfCG8Bi10VE1oJIBK2Ran-uRcfbioLkajn3l1Setfh_XeupL_QRWvIa5UJfsPyA43xQt4jvjiERHG419h_AlfRzRfs4j_JVJON1A1yvKKpJIpAz3iNK46be8lyWZQV5mwauft_Mc0UG6WwJPoejmnQbGg12xafLkW747Xkj0-46p7OnBpMO7UP9x9h-mQLDmMHK_X1CBouknWh6_bDX0KSiJT05IWzXEeiyhUFouAZD-tKQV6NDo3sHKcEUlm1rJIXXt2rTh5SRRQoD1N2ugrStJKoJCryn-OWCy-dcjK0nSu159Hd7S1N0MH7MBYspKnFOvp96BkXahUbEkTerNvOiQl3d9ixy3plieTO-x271fw40SSu2wEs3vs8CwhuDrik22d3fKIH_KzrWT56j77uJdJPGMSz5jEkUncLfnAJJ4z6QE7f_9u8vZE9G02hFelbIUpo66dbazWTkrrSyW9KyqHjvzYVVYDeuj4FYzoCGhrK-N9GDcmVMGVzpo6yofsxmw-g8eMQzA6mOi8q2oFlj4GDVRNbaVTui7rJ-xRekiXi6Slcrl5fE9_O_KM3dpS7Tm72eDLCy9wJdj6lx1gvwBYSmER |
link.rule.ids | 783 |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Mitochondria-targeted+resveratrol+derivatives+act+as+cytotoxic+pro-oxidants&rft.jtitle=Current+pharmaceutical+design&rft.au=Sassi%2C+Nicola&rft.au=Mattarei%2C+Andrea&rft.au=Azzolini%2C+Michele&rft.au=Bernardi%2C+Paolo&rft.date=2014-01-01&rft.eissn=1873-4286&rft.volume=20&rft.issue=2&rft.spage=172&rft_id=info:doi/10.2174%2F13816128113199990034&rft_id=info%3Apmid%2F23701548&rft_id=info%3Apmid%2F23701548&rft.externalDocID=23701548 |